Market Overview

Vetr Urges Hold On Gilead After Kite Merger

Related GILD
Najarian Brothers See Unusual Options Activity In Procter & Gamble And Gilead
With $36.7B In Cash, Bank of America Expects Gilead To Shop For Complements To Drug Pipeline
Gilead withdraws application in Europe for expanded use of Zydelig (Seeking Alpha)

On Friday, the Vetr crowd downgraded its rating on Gilead Sciences, Inc. (NASDAQ: GILD) from 3.5 stars (Buy), issued a week ago, to 3 stars (Hold). Crowd sentiment at the time of this writing was generally cautious, with 62 percent of Vetr user ratings bearish.

Earlier in the week, Gilead announced plans to acquire Kite Pharma Inc (NASDAQ: KITE). Since then, share price in the biotech has jumped by 13.5 percent to $83.75.

The announcement also garnered a fair amount of analyst attention. Argus' David Toung issued an upgrade on the stock from Hold to Buy on Thursday while, two days earlier, Robert Spingarn of Credit Suisse raised his price target on the stock from $79 to $85.

See how crowdsourced ratings could help you time the market.

Currently, the Vetr crowd's average price target on Gilead is up at $86.44,  which is above the average analyst target price of $83.59. More than 2 percent of users are holding $GILD in their watch-lists.

Latest Ratings for GILD

Feb 2018BMO CapitalMaintainsOutperformMarket Perform
Feb 2018Leerink SwannMaintainsMarket PerformMarket Perform
Feb 2018Morgan StanleyMaintainsEqual-WeightEqual-Weight

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: VetrDowngrades Price Target Crowdsourcing Analyst Ratings General


Related Articles (GILD + KITE)

View Comments and Join the Discussion!